慢性乙型肝炎患者外周血单个核细胞内与血清HBV DNA载量的相关性及超微结构研究

目的研究慢性乙型肝炎患者外周血单个核细胞(PBMCs)与血清中HBV DNA载量之间的相关性及PBMCs超微结构的变化。方法应用荧光定量聚合酶链反应(FQ-PCR)检测60例慢性乙型肝炎患者PBMCs与血清中HBV DNA的载量;并采用透射电镜分析观察其中20例PBMCs的超微结构所见。结果血清中HBV DNA载量为(5.25±2.11)log10copies/ml,PBMCs中HBV DNA载量为(3.74±1.08)log10copies/ml,两者的HBV DNA表达呈正相关(r=0.84,P<0.0001)。电镜观察到血清HBVDNA载量高(≥105copies/ml)的患者PBMCs胞浆中易见到HBV颗粒,线粒体膨胀、嵴消失,内质网也可见膨胀。病程5年以上或血清HBV DNA载量<103copies/ml的患者,虽然PBMCs中病毒颗粒不多见,但细胞器多有改变。结论慢性乙型肝炎患者PBMCs与血清中HBV DNA载量呈正相关,可作为疗效观察指标。随着病程延长,尽管血清HBV DNA载量明显减少,但PBMCs细胞器损伤明显,提示机体免疫功能受损。     

乙型肝炎病毒核酸荧光定量及血清标志物与肝功能检测的临床意义

目的探讨乙型肝炎病毒(HBV)感染者 HBV DNA 检出情况及其与血清病毒标志物及肝功能在临床应用的意义.方法采用实时荧光定量聚合酶链反应(FQ‐PCR)检测296例不同血清学类型的 HBV 感染者血清中的 HBV DNA ,同时检测 HBV 血清标志物与肝功能.结果99例 HBeAg (+)标本中 HBV DNA 阳性率为100%,平均 HBV DNA 含量为1.21×107 copy/mL ,其 HBV DNA 检出率和含量与 HBeAg(-)模式的检出情况比较差异有统计学意义(P<0.01);HBsAg (+)与 HBsAg (-)模式比较,HBV DNA 检测结果差异有统计学意义(P<0.01);肝功能正常组与肝功能异常组 HBV DNA 检出率比较差异有统计学意义(P<0.01).58例 HBsAg (-)且肝功能又正常的标本中检出了4例 HBV DNA 阳性.结论实时 FQ‐PCR 定量检测 HBV DNA 与 HBV 血清标记物及肝功能指标联合应用可使诊断更准确,治疗更合理.     

产妇血清与乳汁中乙型肝炎病毒DNA含量相关性研究

目的通过分析乙型肝炎病毒(HBV)携带产妇血清HBV DNA含量与其乳汁中HBV DNA含量相关性,探讨乙型肝炎孕妇母乳喂养的安全性问题,并指导母乳喂养。方法选择在项城市永丰乡中心医院住院分娩HBV携带产妇136例,采用实时荧光定量聚合酶链反应(FQ-PCR)技术测定其血清及产后乳汁中HBV DNA含量。结果 76例血清HBV DNA阳性产妇,乳汁标本中40例阳性,总阳性率为52.6%。其中22例血清HBVDNA含量在1.0×103～1.0×105 U/mL者,乳汁标本中阳性率为9.0%;30例血清HBV DNA含量在1.0×105～1.0×107 U/mL者,乳汁标本中阳性率为60.0%,24例血清HBV DNA含量在1.0×107～1.0×109 U/mL者,乳汁标本中阳性率为83.3%。乙型肝炎产妇血清HBV DNA含量与乳汁中HBV DNA含量呈正相关。结论 HBV携带产妇均应作血清、乳汁HBV DNA定量检测,根据其传染危险性采取措施,正确指导母乳喂养,确定哺乳方式,从而降低新生儿HBV感染率。     

乙型肝炎病毒DNA与标本物含量及肝功能生化指标间关系探讨

目的探讨血清中乙型肝炎病毒(HBV)DNA含量与HBV标志物[乙型肝炎表面抗原(HBsAg)、乙型肝炎e抗原(HBeAg)]及肝功能指标间的相关性。方法抽取南平市人民医院肝内科住院的200例HBV携带患者血清样本。采用荧光定量聚合酶链反应(PCR)检测血清样本中HBV DNA含量,采用酶联免疫吸附试验(ELISA)测定血清样本中HBV标志物含量,同时检测肝功能。3项检测指标使用同一患者标本,分析3项指标之间的相关性。结果经相关性分析,HBV DNA与肝功能指标的r在±0.2以内,差异无统计学意义(P>0.05);HBsAg、HBeAg含量与肝功能指标的r在±0.2以内,差异无统计学意义(P>0.05);HBsAg、HBeAg含量与HBVDNA含量的r分别为0.457、0.568,差异有统计学意义(P<0.01)。结论 HBsAg、HBeAg含量只反映HBV在血清中的复制情况,不能以HBsAg、HBeAg含量及病毒载量的大小作为判断肝功能受损程度的指标;要综合分析HBV DNA含量与HBV标志物定量检测结果及肝功能,这样才能更有效地对疾病进行评估。     

乙型肝炎病毒YMDD变异株的检测及其临床意义

目的探讨慢性乙型肝炎患者HBV YMDD变异的情况、相关影响因素及临床意义,为临床诊断和治疗提供依据。方法对100例慢性乙型肝炎患者采用实时荧光PCR法检测血清中HBV YMDD变异及HBV DNA载量。结果 100例乙肝患者中检出HBV YMDD变异共13例(阳性率13%),其中YIDD变异7例,YVDD变异5例,YIDD/YVDD共生变异1例。13例YMDD变异患者HBV DNA在(1.77×105~1×108)IU/mL,丙氨酸转氨酶(ALT)水平18.1~273.5U/L。结论未发现慢性乙型肝炎患者的性别、年龄、乙型肝炎E抗原(HBeAg)状态、HBV DNA载量及ALT水平与HBV YMDD变异检出率之间存在相关性,差异无统计学意义(P0.05)。     

不同HBV感染模式产妇乳汁中HBV-DNA载量及肝功能分析

目的研究乙型肝炎阳性产妇感染模式,以及血清中乙型肝炎病毒(HBV)-DNA载量与乳汁中HBV-DNA载量的关系,乳汁中HBV-DNA载量与产妇肝功能的关系,评价母乳喂养的安全性。方法对267例HBV携带产妇,用酶联免疫吸附试验(ELISA)法检测乙型肝炎表面抗原(HBsAg)和乙型肝炎e抗原(HBeAg),用荧光定量PCR技术检测血清中和乳汁中HBVDNA载量,采用速率法检测丙氨酸氨基转移酶(ALT)。结果 109例HBsAg和HBeAg双阳性的产妇,其乳汁HBV-DNA阳性率为76.1%,158例HBsAg阳性而HBeAg阴性产妇乳汁HBV-DNA阳性率为3.2%,差异有统计学意义(P0.05)。观察产妇其血清中携带不同载量的HBV-DNA,分别为HBV-DNA500、500~1.0×10~5、1.0×10~5 copies/mL 3组,其两两比较乳汁中HBV-DNA载量差异有统计学意义(P0.05),且血清中HBV-DNA载量与乳汁中HBV-DNA载量呈正相关关系;乳汁中HBVDNA阳性与乳汁中HBV-DNA阴性产妇血清ALT进行比较,差异有统计学意义(P0.05)。结论 HBsAg和HBeAg双阳性和血清中HBV-DNA1.0×10~5 copies/mL的产妇不宜母乳喂养,同时乳汁中HBV-DNA载量较高的产妇应同时密切监测肝功能,以防发生肝损伤。     

HBV DNA定量检测及其与HBV标志物的相关性探讨

目的探讨乙型肝炎病毒(HBV)DNA与不同类型HBV免疫标志物之间的关系,为临床诊断和治疗提供有价值的判断标准。方法采用酶联免疫吸附试验(ELISA法)对220例血清标本进行HBV免疫标志物检测,同时用荧光定量聚合酶链反应(FQ-PCR)检测HBV DNA含量。结果 96例乙型肝炎表面抗原(HBsAg)、乙型肝炎核心抗体(抗-HBc)、乙型肝炎e抗原(HBeAg)阳性(+)标本中HBV DNA阳性检出率为91.7%(88/96);100例HBsAg(+)/抗-HBe(+)抗-HBc(+)标本中HBV DNA阳性检出率为20.0%(20/100)。HBsAg阳性组与HB-sAg阴性组、HBeAg阳性组与HBeAg阴性组的DNA载量比较差异有统计学意义。结论 FQ-PCR可以检测HBV感染的真实性和复制情况,其与ELISA法检测HBV血清标志物相结合,对乙型肝炎的临床诊断及治疗方案的选择、疗效观察及预后判断具有极其重要的作用。     

慢性乙型肝炎患者肝组织乙型肝炎病毒共价闭合环状DNA的定量检测

目的 探讨肝组织乙型肝炎病毒共价闭合环状DNA(HBV CccDNA)水平与病毒复制、肝组织损伤的关系.方法 应用荧光定量聚合酶链反应(PCR)方法检测46例慢性乙型肝炎患者肝组织HBV CccDNA水平,同时检测肝组织和血清中HBV DNA、肝细胞乙型肝炎表面抗原(HBsAg)和乙型肝炎核心抗原(HBcAg)表达及肝功能.结果 将肝组织中HBVCccDNA定量水平分为低(＜104copies/mg)、中(104～106copies/mg)、高(＞106 copies/mg)3组,3组中HBsAg阳性表达差异无统计学意义,但105～106copies/mg和＞107copies/mg组HBcAg阳性表达高于＜104 copies/mg组,分别为105～106copies/mg组HBcAg表达14例(63.6%)和＞107copies/mg组7例(77.8%)vs＜104copies/mg组2例(13.3%)(P＜0.01);HBeAg阳性组肝组织中HBV CccDNA和肝组织总HBV DNA均显著高于HBeAg阴性组,分别为肝组织中HBV CccDNAHBeAg阳性组(8.72±1.94)log10 copies/mg vs HBeAg阴性组(6.54±1.56)log10 copies/mg;肝组织中HBV DNAHBeAg阳性组(7.45±1.82)1og10 copies/mg vs HBeAg阴性组(5.27±1.48)log10 copies/mg(均P＜0.01);肝组织中HBV CccDNA与肝组织总HBV DNA、血清HBV DNA呈正相关(均P＜0.05);而与肝组织炎症程度、肝纤维化程度、丙氨酸转氨酶(ALT)和天冬氨酸转氨酶(AST)无相关性.结论 肝组织中HBV CccDNA定量能准确反映病毒复制水平,但不能将其视为肝组织损伤的标志.     

HBV DNA与乙型肝炎血清学模式及GGT、ALT的关系

目的探讨血清HBV病毒载量与血清学标志物和肝功能指标ALT、GGT之间的关系。方法用FQ-PCR法检测乙型肝炎病毒载量、ELISE法检测乙型肝炎血清学标志物及酶法检测肝功能指标ALT、GGT,对222例患者血清标本的上述3种指标结果进行分析。结果在3种常见的血清学模式中,HBsAg、HBeAg和抗-HBc阳性者(135模式)HBVDNA阳性率为77.8%,肝功能中ALT和(或)GGT异常占54.0%;HBsAg、HBeAb和抗-HBc阳性者(145模式)HBVDNA阳性率为43.2%,肝功能中ALT和(或)GGT异常占48.4%;HBsAg、抗-HBc阳性者(15模式)HBVDNA阳性率为48.4%,肝功能中ALT和(或)GGT异常占45.3%。结论 HBV病毒载量与乙型肝炎血清学标志物之间具有相关性,肝功能指标ALT、GGT与乙型肝炎血清学标志物之间差异无统计学意义,HBV病毒载量与肝功能指标ALT、GGT具有一定的相关性。     

乙型肝炎表面抗原阳性肝硬化患者前S1抗原、e抗原及乙型肝炎病毒DNA结果分析

目的探讨乙型肝炎病毒(HBV)表面抗原(HBsAg)阳性肝硬化患者血清中HBV前S1抗原(前S1抗原)、HBV e抗原(HBeAg)及HBV核酸定量检测(HBV DNA)相关性。方法 2008年7月-2011年5月对97例HBsAg阳性肝硬化住院患者和50份HBsAg阴性的健康体检者血清进行前S1抗原、HBV血清标志物检测及实时荧光定量PCR检测HBV DNA结果进行分析。结果 97份HBsAg阳性肝硬化患者血清中,前S1抗原、HBeAg及HBV DNA阳性率分别为53.6%(52/97)、22.7%(22/97)及61.8%(60/97)。22例HBeAg阳性血清中,前S1抗原阳性18例(81.8%),HBV DNA阳性20例(90.9%)。75例HBeAg阴性血清中,前S1抗原阳性34例(45.3%),HBV DNA阳性40例(53.3%),两者的前S1抗原与HBV DNA结果间都具有很好的相关性。HBV DNA含量与前S1抗原及HBeAg阳性结果显示:HBsAg阳性的肝硬化患者血清中HBV DNA阴性率为38.1%(含量<103 copies/mL),而阳性检出率HBV DNA含量主要集中在103～105 copies/mL,占81.7%(49/60),HBV DNA含量>105 copies/mL占18.3%(11/60)。结论 HBsAg阳性的肝硬化患者血清中主要以HBV非HBeAg阳性血清学模式为主,HBV DNA阳性检出率的含量主要集中在103～105 copies/mL。前S1抗原在HBeAg阳性血清中与其含有HBsAg病毒及HBeAg阳性患者具有很好的相关性,而在HBeAg阴性血清中存在着差异。     

The clinical features of chronic hepatitis C are not affected by the coexistence of hepatitis B virus DNA in patients negative for hepatitis B surface antigen

Hepatitis B virus (HBV) DNA has been detected in the sera of hepatitis patients who are negative for hepatitis B surface antigen (HBsAg) by polymerase chain reaction (PCR). The purpose of the present study was to clarify the clinical characteristics of patients with chronic hepatitis C who are negative for serum HBsAg and positive for HBV DNA. The subjects included 49 patients with chronic hepatitis C who were negative for serum HBsAg and 119 blood donors who served as healthy controls. Serum samples were tested for the presence of HBV DNA by the nested PCR method. Serum HBV DNA was detected in 18 (37.7%) of the 49 chronic hepatitis C patients and in none (0%) of the 119 blood donors. Among the hepatitis C patients, HBV DNA was detected in 20.7% of those who were negative for all HBV-associated markers and in 57.1% of those who were positive for one or more HBV-associated marker. The HBV DNA-positive rate among those in each F stage did not significantly differ. The liver function parameters of the HBV DNA-positive and the HBV DNA-negative chronic hepatitis C patients did not significantly differ. These results suggest that hepatitis C virus is frequently coinfected with serum HBsAg-negative HBV, and that the incidence of HBV infection in blood donors is low. However, it is considered that HBsAg-negative HBV infection does not modify the blood biochemical features of chronic hepatitis C.     

拉米夫定在慢性乙型肝炎患儿外周血Th17细胞变化的研究

目的研究拉米夫定在慢性乙型肝炎(下称慢性乙肝)患儿外周血Th17细胞变化的特征及意义。方法选取该院慢性乙肝患儿45例作为慢性乙肝组,另选取23例健康儿童作为健康对照组。慢性乙肝组患儿给予拉米夫定治疗1年。抽取健康对照组、慢性乙肝组治疗前及治疗1年后外周静脉血,检测血清中乙型肝炎病毒表面标志物(HBV-M)、乙型肝炎病毒核酸定量(HBV-DNA)、丙氨酸氨基转移酶(ALT)及外周血中Th17细胞特征。结果经拉米夫定治疗,慢性乙肝患儿ALT、HBV-DNA载量明显降低,其中26例患儿出现HBV-DNA转阴,4例出现HBeAg转阴。慢性乙肝组治疗前Th17细胞频率明显高于健康对照组(P0.05),经拉米夫定治疗1年后外周血Th17细胞频率较治疗前显著降低,但仍高于健康对照组(P0.05)。治疗后HBV-DNA转阴患儿较未转阴患儿的Th17细胞频率明显降低。结论拉米夫定治疗儿童慢性乙肝能有效抑制病毒复制,且可降低患儿外周血中Th17细胞的频数。     

State of hepatitis B virus DNA in peripheral blood mononuclear cells from persistently infected individuals: correlation with e antigen and viral DNA in the serum as well as with the activity of liver disease

Peripheral blood mononuclear cells (PBMC) were harvested from 76 asymptomatic carriers of hepatitis B virus (HBV) and 100 patients with type B chronic liver disease. DNA was extracted from cells and tested for the binding with radiolabeled HBV DNA probe by Southern blot hybridization technique. Among 34 asymptomatic carriers who had hepatitis B e antigen (HBeAg) and HBV DNA in the serum, HBV DNA was detected in 29 (85%) PBMC. In remarkable contrast, of the remaining 42 carriers seronegative for HBeAg, only 1 (2%) had HBV DNA in the serum, and none exhibited HBV DNA in PBMC. Among 32 patients seropositive for HBeAg, HBV DNA was detected in 28 (88%) sera, and in 24 (75%) PBMC. Of 68 patients seronegative for HBeAg, HBV DNA was found in 10 (15%) sera, and in 7 (10%) PBMC. Among 62 cases with HBV DNA in PBMC, only 1 had it integrated into the host's DNA. The remaining 61 had free HBV DNA in PBMC. Only 8 of them possessed replicative intermediate forms of HBV DNA, with molecular sizes less than 2.0 kilobases as observed in liver infected with HBV, and they all were patients with chronic active hepatitis. HBV DNA was not detectable in PBMC from 172 controls comprising 44 healthy individuals and 128 patients with non-A, non-B hepatitis. Based on these results, the state of HBV DNA in PBMC reflects the phase of HBV infection with HBeAg in the serum, and a high activity of hepatitis accompanied by active HBV replication.     

乙型肝炎病毒DNA定量与血清学标志物的关系

目的探讨乙型肝炎（下称乙肝）病毒（HBV）DNA定量与HBV血清学标志物（HBVM）的关系。方法采用实时荧光定量聚合酶链反应（FQ-PCR）检测225例乙肝感染者血清的HBV DNA含量,并用酶联免疫吸附试验（ELISA）对其血清学标志物进行检测。结果在不同HBV M模式中,HBV DNA与HBV前S1抗原（preS1Ag）总检出率差异无统计学意义。在模式乙肝病毒表面抗原（HBsAg）（＋）、乙肝病毒e抗原（HBeAg）（＋）和抗核心抗原抗体（＋）中血清HBV DNA含量明显高于其他模式。在139例HBV DNA阳性的标本中,HBV DNA与preS1Ag检出率差异无统计学意义（P〉0．05）,HBV DNA与HBeAg检出率差异有统计学意义（P〈0．01）,同时preS1Ag阳性组HBV DNA定量值显著高于preS1Ag阴性组。结论HBV DNA或preS1Ag与HBV复制密切相关,preS1Ag较HBeAg更能敏感反应HBV复制,联合检测HBV DNA与HBVM在乙肝的诊断治疗中更有重要的临床指导价值。     

Serum HBV-DNA (hepatitis B virus DNA) in acute and chronic hepatitis B infection

HBV DNA was measured in the sera of 69 patients with hepatitis B virus infections. Sixteen patients had acute hepatitis B, 24 had chronic active hepatitis (CAH), 6 had chronic persistent hepatitis (CPH), 5 had cirrhosis without CAH and 18 were asymptomatic HBsAg carriers. In patients with acute hepatitis B who recovered, HBV DNA was present in the serum transiently early in the illness. HBV DNA persisted in the serum in the two patients who developed chronic hepatitis. Sera of 23 of 24 patients with CAH were persistently positive for HBV DNA. There was no relationship between the quantity of HBV DNA in the serum and the histological intensity of activity. Thirteen of the 24 patients with CAH had histological evidence of cirrhosis in addition to CAH and HBV DNA was detected in the sera of all 13. The sera of 2 of 6 patients with CPH were positive for HBV DNA. In one it was positive only where there was clinical evidence of reactivation of HBV infection. The other patient subsequently developed CAH. Sera of 5 patients with established HBsAg positive cirrhosis but without evidence of CAH were negative for HBV DNA. Two of these patients had hepatocellular carcinoma. Sera of 18 asymptomatic anti-HBe positive carriers with normal ALT were negative for HBV DNA. HBeAg and HBV DNA were not always found in the serum together. In acute hepatitis 5 patients with HBV DNA in the serum were HBeAg positive, but in 6 patients the sera were HBeAg positive inthe absenceof HBV DNA.     

乙型肝炎患者外周血单个核细胞和血清中HBV-DNA含量与HBVM间关系的探讨

目的探讨乙肝患者外周血单个核细胞和血清中HBV-DNA含量及其与HBVM之间的关系。方法67例乙肝患者为检测对象,36健康献血者为对照组,分别用FQ-PCR定量测定,内对照法定量测定血清HBV-DNA。免疫荧光定量测定HBVM。结果外周血单个核细胞HBV-DNA检出阳性率为67．2％（45／67）,与血清的符合率为80．7％,但慢性乙肝患者外周血单个核细胞HBV-DNA检出率高于血清,且与病情呈正相关。结论三个指标的联合检测有助与反映肝细胞病毒复制情况。对进一步指导抗病毒治疗有一定意义。     

乙肝患者血清HBV外膜大蛋白与HBV DNA的关系

目的:通过对乙型肝炎(乙肝)患者血清乙型肝炎病毒外膜大蛋白(HBV-LP)和HBV DNA的检测,探讨二者在判断乙肝病情和HBV复制情况时的相关性及其在临床上的意义。方法:采用荧光定量PCR方法对238份乙肝患者血清的HBV DNA进行检测,采用酶联免疫吸附试验,对上述标本进行HBV-LP和HBV血清免疫学标志物(HBV-M)模式的检测。结果:HBV-LP检出率与HBV DNA的检出率差异有显著性(P<0.05),不同HBV-M模式的HBV DNA与HBV-LP的检出结果差异有显著性(P<0.05),HBV DNA拷贝数与HBV-LP的表达有相关性(r=0.677,P<0.001)。结论:血清中HBV-LP的含量与HBV DNA的拷贝数具有较好的相关性,但HBV-LP尚不能完全代替HBV DNA的检测来反映HBV复制情况。     

Immunological and Antiviral Responses After Therapeutic DNA Immunization in Chronic Hepatitis B Patients Efficiently Treated by Analogues

A substudy of a phase I/II, prospective, multicenter clinical trial was carried out to investigate the potential benefit of therapeutic vaccination on hepatitis B e antigen-negative patients with chronic hepatitis B (CHB), treated efficiently with analogues. Patients were randomized in 2 arms, one receiving a hepatitis B virus (HBV) envelope DNA vaccine, and one without vaccination. At baseline, HBV-specific interferon (IFN)-γ–producing T cells were detected in both groups after in vitro expansion of peripheral blood mononuclear cells. Vaccine-specific responses remained stable in the vaccine group, whereas in the control group the percentage of patients with HBV-specific IFN-γ–producing T cells decreased over time. The vaccine-specific cytokine-producing T cells were mostly polyfunctional CD4⁺ T cells, and the proportion of triple cytokine-producer T cells was boosted after DNA injections. However, these T-cell responses did not impact on HBV reactivation after stopping analogue treatment. Importantly, before cessation of treatment serum hepatitis B surface antigen (HBsAg) titers were significantly associated with DNA or HBsAg clearance. Therapeutic vaccination in CHB patients with persistent suppression of HBV replication led to the persistence of T-cell responses, but further improvements should be searched for to control infection after treatment discontinuation.     

肝组织HBV cccDNA与HBV复制水平的相关性分析

目的 探讨乙肝患者肝组织中乙型肝炎病毒（HBV ） cccDNA与血清 HBV DNA及乙肝病毒e抗原（HBeAg）含量的关系。方法 采用实时荧光定量聚合酶链反应检测乙肝患者肝组织 HBV cccDNA和血清HBV DNA ,采用化学发光法检测其血清中 HBeAg。结果 肝组织HBV cccDNA与血清HBV DNA定量呈正相关（ r ＝0．806,P ＜0．01）,与血清 HBeAg定量值无相关关系（ r ＝0．219,P ＞0．05）。结论 血清HBeAg阳性组病毒复制较阴性组活跃,HBV DNA阴性不能完全反映肝组织内 HBV是否存在复制,而检测肝组织HBV cccDNA可精确反映肝内 HBV复制情况。     

乙型肝炎病毒DNA含量与血清标志物的关系

目的 探讨乙型肝炎患者血清乙型肝炎病毒（HBV）DNA定量与乙肝血清标志物关系。方法 采用定量聚合酶链反应（PCR）法检测354例乙型肝炎患者血清中DNA含量,与HBV标志物作对比研究。结果 血清HBeAg阳性组HBVDNA含理明显高于抗-HBe或抗-HBc阳性组,而后两组HBVDNA检出率仍较高,乙型肝炎肝硬化组阳性率明显低于慢性乙型肝炎组,且含量较低。结论 定量PCR法检测HBVDNA检出率仍较高,乙型肝炎肝硬化组阳性率明显低于慢性乙型肝炎组,且含量较低。结论 定量PCR法检测HBV DNA具有较强的特异性和灵敏度,为临床了解病毒复制情况,制定治疗方案及疗效观察提供了确切依据。